FDA vaccine advisers set to review Moderna’s mRNA flu shot for traditional approval

The Food and Drug Administration’s vaccine advisory committee is set to review Moderna’s proposed mRNA influenza vaccine ahead of a key meeting Thursday, according to a report by The Hill. The discussion is part of the FDA’s process for obtaining expert input on vaccine applications before the agency makes a final determination.

Moderna is seeking traditional approval, rather than an alternative pathway, for an mRNA flu vaccine intended for use by patients in the eligible population described in its application, The Hill reported. The vaccine advisory committee meeting is expected to focus on the company’s clinical evidence and the overall benefit-risk profile, including immunogenicity and safety data.

Ahead of the meeting, The Hill reported that FDA’s vaccine advisors appear open to Moderna’s candidate. Public advisory committee proceedings typically include presentations from the applicant, FDA staff, and outside experts, followed by committee discussion and votes on specific questions posed by the agency.

The FDA’s advisory committee recommendation is not the final regulatory decision, but it can shape how FDA evaluates the application. FDA staff weigh committee input along with review reports and the full record from the application when determining whether to approve the product and under what labeling and post-approval requirements, the process generally follows.

For patients and providers, the practical stakes are largely tied to whether the product can receive traditional approval, which affects how it is marketed, distributed, and incorporated into routine seasonal influenza vaccination plans. For health systems, an approved vaccine can also influence procurement planning for the upcoming flu season and related logistics such as storage, handling, and administration protocols.

For companies, the timing and outcome of advisory committee review can affect timelines for manufacturing scaling and the broader regulatory pathway. If the FDA follows with an approval decision after the committee meeting, Moderna would move to the next steps required for market authorization, including final FDA determinations on labeling and any additional studies the agency may request.